Stock Scorecard
Stock Summary for Genmab (GMAB) - $32.02 as of 12/5/2025 3:00:37 PM EST
Total Score
18 out of 30
Safety Score
68 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for GMAB
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GMAB
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GMAB
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for GMAB
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for GMAB (68 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 9 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for GMAB
Financial Details for GMAB
Company Overview |
|
|---|---|
| Ticker | GMAB |
| Company Name | Genmab |
| Country | USA |
| Description | Genmab AS is a leading biotechnology firm headquartered in Copenhagen, Denmark, specializing in the creation of differentiated antibody therapeutics for oncology and other severe diseases. Renowned for its innovative approach and cutting-edge proprietary technologies, the company has established a robust pipeline of next-generation therapies through strategic alliances and collaborations. With a steadfast focus on enhancing patient outcomes via targeted immunotherapies, Genmab is strategically positioned to leverage growth opportunities within the evolving oncology landscape, making it an attractive prospect for institutional investors. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/5/2026 |
Stock Price History |
|
| Last Day Price | 32.02 |
| Price 4 Years Ago | 39.56 |
| Last Day Price Updated | 12/5/2025 3:00:37 PM EST |
| Last Day Volume | 781,623 |
| Average Daily Volume | 1,905,448 |
| 52-Week High | 33.65 |
| 52-Week Low | 17.23 |
| Last Price to 52 Week Low | 85.84% |
Valuation Measures |
|
| Trailing PE | 14.04 |
| Industry PE | 47.47 |
| Sector PE | 89.35 |
| 5-Year Average PE | 31.34 |
| Free Cash Flow Ratio | 11.20 |
| Industry Free Cash Flow Ratio | 14.06 |
| Sector Free Cash Flow Ratio | 28.79 |
| Current Ratio Most Recent Quarter | 6.03 |
| Total Cash Per Share | 2.86 |
| Book Value Per Share Most Recent Quarter | 93.41 |
| Price to Book Ratio | 3.39 |
| Industry Price to Book Ratio | 34.08 |
| Sector Price to Book Ratio | 33.16 |
| Price to Sales Ratio Twelve Trailing Months | 5.16 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.69 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.82 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 615,993,000 |
| Market Capitalization | 19,724,095,860 |
| Institutional Ownership | 10.28% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 107.60% |
| Annual Earnings Growth | 80.24% |
| Reported EPS 12 Trailing Months | 2.28 |
| Reported EPS Past Year | 1.50 |
| Reported EPS Prior Year | 1.74 |
| Net Income Twelve Trailing Months | 6,570,238,720 |
| Net Income Past Year | 7,844,000,000 |
| Net Income Prior Year | 4,352,000,000 |
| Quarterly Revenue Growth YOY | 17.40% |
| 5-Year Revenue Growth | 32.03% |
| Operating Margin Twelve Trailing Months | 44.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,761,000,000 |
| Total Cash Past Year | 9,858,000,000 |
| Total Cash Prior Year | 14,867,000,000 |
| Net Cash Position Most Recent Quarter | 824,000,000 |
| Net Cash Position Past Year | 9,858,000,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 937,000,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.86 |
| Total Stockholder Equity Past Year | 36,697,000,000 |
| Total Stockholder Equity Prior Year | 31,610,000,000 |
| Total Stockholder Equity Most Recent Quarter | 5,751,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 2,994,138,490 |
| Free Cash Flow Per Share Twelve Trailing Months | 4.86 |
| Free Cash Flow Past Year | 7,584,000,000 |
| Free Cash Flow Prior Year | 7,004,000,000 |
Options |
|
| Put/Call Ratio | 0.03 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.57 |
| MACD Signal | 0.41 |
| 20-Day Bollinger Lower Band | 20.80 |
| 20-Day Bollinger Middle Band | 28.15 |
| 20-Day Bollinger Upper Band | 35.49 |
| Beta | 0.79 |
| RSI | 62.45 |
| 50-Day SMA | 23.53 |
| 150-Day SMA | 29.01 |
| 200-Day SMA | 30.77 |
System |
|
| Modified | 12/6/2025 12:18:37 AM EST |